Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16046274 | 0.90 | FAAH (0.53) | FAAHEGLN1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL11484529 | 0.86 | FAAH (0.58) | FAAHOR51E2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL1300141 | 0.86 | FAAH (0.53) | FAAHEGLN1OR51E2ALDH1A1HSD17B10 | |
| SCHEMBL16046412 | 0.86 | FAAH (0.47) | FAAHEGLN1MAPK1SLC13A3OR51E2 | |
| SCHEMBL4445881 | 0.82 | FFAR3 (0.44) | EGLN1MAPK1SLC13A3OR51E2ALDH1A1 | |
| Alpha-Ketoglutaric Acid SCHEMBL30292150 | 0.81 | EGLN1 (0.48) | FAAHEGLN1MAPK1SLC13A3OR51E2 | |
| SCHEMBL3533002 | 0.81 | GAA (0.50) | FAAHALDH1A1SMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL2402800 | 0.80 | EGLN1 (0.50) | EGLN1MAPK1SLC13A3OR51E2ALDH1A1 | |
| SCHEMBL18101453 | 0.80 | FAAH (0.60) | FAAHEGLN1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL112407 | 0.80 | CES2 (0.55) | FAAHEGLN1ALDH1A1LMNAFFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2555803-B1 | PROCESS FOR PREPARING HYPERPOLARIZED SUBSTRATES AND METHOD FOR MRI | BRACCO IMAGING SPA (IT) | 2018-09-12 | — | — | EP | claimed |
| US-9694090-B2 | Process for preparing hyperpolarized substrates and method for MRI | BRACCO IMAGING S.P.A. (IT) | 2017-07-04 | — | — | US | claimed |
| US-20130096420-A1 | Process For Preparing Hyperpolarized Substrates And Method For MRI | BRACCO IMAGING S.P.A. (IT) | 2013-04-18 | — | — | US | claimed |
| EP-2555803-A1 | PROCESS FOR PREPARING HYPERPOLARIZED SUBSTRATES AND METHOD FOR MRI | Bracco Imaging S.p.A (IT) | 2013-02-13 | — | — | EP | claimed |
| WO-2011124672-A1 | PROCESS FOR PREPARING HYPERPOLARIZED SUBSTRATES AND METHOD FOR MRI | BRACCO IMAGING SPA (IT) | 2011-10-13 | — | — | WO | claimed |
| US-20090048153-A1 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2009-02-19 | — | — | US | claimed |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | ISHIBASHI, MICHIO (JP) | 2003-09-25 | — | — | US | claimed |
| EP-1277747-A1 | SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE | Ishibashi, Michio (JP) | 2003-01-22 | — | — | EP | claimed |
| EP-4735906-A1 | SYSTEMS AND METHODS FOR HYPERPOLARIZED NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND MAGNETIC RESONANCE IMAGING | NVision Imaging Technologies GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4587413-A1 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | NVision Imaging Technologies GmbH (DE) | 2025-07-23 | — | — | EP | disclosed |
| EP-4587850-A1 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | NVision Imaging Technologies GmbH (DE) | 2025-07-23 | — | — | EP | disclosed |
| US-20250091980-A1 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | NVISION IMAGING TECHNOLOGIES GMBH (DE) | 2025-03-20 | — | — | US | disclosed |
| CN-119587524-A | Application of alpha ketoglutarate prodrug in preparation of medicines for treating myelodysplastic syndrome | 浙江大学 | 2025-03-11 | — | — | CN | disclosed |
| WO-2025003849-A1 | SYSTEMS AND METHODS FOR HYPERPOLARIZED NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY AND MAGNETIC RESONANCE IMAGING | NVISION IMAGING TECHNOLOGIES GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| CN-1293674-A | Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient | TORAY INDUSTRIES (JP) | 2001-05-02 | — | — | CN | disclosed |
| WO-2000053313-A2 | LANTHANIDE CATALYSTS FOR SYNTHESIS OF COMPOUNDS AND COMBINATORIAL LIBRARIES | ARQULE, INC. (US) | 2000-09-14 | — | — | WO | disclosed |
| US-4876251-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-10-24 | — | — | US | disclosed |
| EP-0249909-A1 | Tricyclic penam compounds, their production and their use | Takeda Chemical Industries, Ltd. (JP) | 1987-12-23 | — | — | EP | disclosed |
| EP-0056489-B1 | A CONTINUOUS PROCESS FOR THE PREPARATION OF ADIPIC ACID | BASF Aktiengesellschaft (DE) | 1984-08-22 | — | — | EP | disclosed |
| EP-0056489-A1 | A continuous process for the preparation of adipic acid | BASF Aktiengesellschaft (DE) | 1982-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048153-A1 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME | TST, SQOR, QSOX1 | FAAH 1021/4885EGLN1 739/4885MAPK1 2105/4885 |
| US-20030181506-A1 | Selective preventives/remedies for progressive lesions after organ damage | CCL11, CD68, CCL2 | FAAH 2777/4885EGLN1 4294/4885MAPK1 2510/4885 |
| US-20130096420-A1 | Process For Preparing Hyperpolarized Substrates And Method For MRI | HOGA1, HAMP, GLS2 | FAAH 768/4885EGLN1 38/4885MAPK1 1116/4885 |
| US-20250091980-A1 | SYSTEMS AND METHODS FOR GENERATION OF HYPERPOLARIZED MATERIALS | GLS2, HNMT, FH | FAAH 2469/4885EGLN1 422/4885MAPK1 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.